Drug intelligence / Profile preview

Uc.63+ siRNA

Development stage: Preclinical
Lead developer: Hiroshima University
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

Uc.63+ siRNA is an experimental small interfering RNA (siRNA) designed to target and silence the expression of the transcribed ultraconserved region Uc.63+ (T-UCR Uc.63+). Uc.63+ is a non-coding RNA that is significantly upregulated in urothelial carcinoma (UC) compared to normal bladder tissues. Research has demonstrated that Uc.63+ promotes cell proliferation and resistance to cisplatin (CDDP) chemotherapy by modulating androgen receptor (AR) signaling. By utilizing RNA interference to knock down Uc.63+, this siRNA increases the sensitivity of bladder cancer cells to cisplatin and can re-sensitize resistant cells, suggesting its potential as a therapeutic strategy for overcoming chemoresistance in muscle-invasive bladder cancer.

Other names: siRNA targeting Uc.63+Uc.63+ small interfering RNA

Targets

Uc.63+ (Transcribed ultraconserved region Uc.63+)

Beyond the preview

Go deeper on Uc.63+ siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uc.63+ siRNA.

Explore the full profile